Voyager Therapeutics, Inc. · NASDAQ:VYGR
Voyager Therapeutics — CTAD 2025
10 slides from Voyager Therapeutics's conference presentation, December 2025
Slide 1: Results of a Phase 1 Study of VY7523 in Healthy Adults
Results of a Phase 1, randomized, placebo- controlled, double-blind study to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of VY7523, a tau-targeting therapeutic, in healthy adult participants Elena Ratti, Monroe Butler, Naomi Muse, Sarah Piantedosi, Thrusha Ch
Slide 2: Affiliations
Affiliations Elena Ratti is a full-time employee of Voyager Therapeutics, Inc. 2 | CO N F I D E N T I AL
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “anticipate,” “expect,” “believe,” “plan,” “estimate,
Slide 4: Background
Background Normal protein • Accumulation and seeding of pathological tau in Alzheimer’s disease (AD) is believed to propagate Pathological misfolded protein Template-directed preferentially through brain regions that are synaptically misfolding Pathological and functionally connected misfolded prote
Slide 5: First-in-Human Study of VY7523
First-in-Human Study of VY7523 SINGLE ASCENDING DOSE STUDY IN HEALTHY ADULT PARTICIPANTS Cohort 6 Cohort 5 Cohort 4 Screening Cohort 3 Cohort 2 Cohort 1 Outpatient follow-up Single dose + 12 weeks (Cohort 1-3) 48 hrs inpatient observation 16 weeks (Cohort 4-6) Sentinel Participants (N=2) Remaining P
Slide 6: First-in-Human Study of VY7523
First-in-Human Study of VY7523 SINGLE ASCENDING DOSE STUDY IN HEALTHY ADULT PARTICIPANTS Primary Secondary Population Objectives Administration Sites Endpoints Endpoints • Up to 48 healthy • Safety, tolerability, • Incidence of treatment- • Serum VY7523 PK • Intravenous • 1 site (Clinical adult part
Slide 7: Demographics and Dispositions
Demographics and Dispositions Pooled Placebo All VY7523 (N = 12) (N = 36) Female 5 (42%) 16 (44%) Sex Male 7 (58%) 20 (56%) Black or African American 3 (25%) 3 (8%) White 9 (75%) 31 (86%) Race White, American Indian or Alaska Native 0 (0%) 1 (3%) White, Black or African American 0 (0%) 1 (3%) Hispan
Slide 8: SAD Safety Summary
SAD Safety Summary • No deaths, SAEs or severe AEs, No infusion related reactions (IRRs) • All TEAEs were mild to moderate in severity; no trends in AE severity across the ascending doses • No clinically significant changes in Labs (chemistry, hematology, coagulation), vital signs (including orthost
Slide 9: Pharmacokinetics Summary
Pharmacokinetics Summary Pharmacokinetics Immunogenicity • VY7523 demonstrated dose • Low immunogenicity profile following proportional and linear PK single dose – Mean half-life ranged between 22 to 29 – One possible treatment emergent ADA days which supports monthly dosing observed – not associate
Slide 10: Summary and Conclusions
Summary and Conclusions • VY7523 was well tolerated, no SAEs, no infusion related reactions • VY7523 showed dose proportional and linear pharmacokinetics – Half-life supports monthly dosing – Demonstrated CNS penetrance with %CSF-to-serum of ~0.3% • Phase 1 SAD and chronic GLP toxicology data suppor